Cancure
  • Home
  • About
    • Vision
    • Board & Management
    • Scientific Advisors
  • Cancer
    • Current Treatments
    • Market
  • Therapies
    • Genvax – lead candidate CNC118
    • Galectin – lead candidate CNC225
    • Mitocans – lead candidate CNC332
    • Combination Therapy
    • Genvax vs. CAR-T
    • Development Program
    • References
  • Investors
    • Investors Snapshot
    • News
    • Public Documents
  • Contact
  • Glossary of Terms
  • Search
  • Menu Menu
Cancure

ABOUT

 

Cancure Limited (“Cancure”) is a cancer drug development company established in 2012 on the Gold Coast, Queensland, Australia to consolidate and capitalise on over a decade of immuno-oncology research and development. Cancure aims to maximise patient response rates and hasten the evolution of cancer treatments into cancer cures.2313213

 

Cancure’s three development programs – Genvax, Galectin, and Mitocans – are focused on the treatment and cure of cancer. Building on over a decade of leading research in each program, Cancure aims to advance three drug candidates to Phase 1 (Ph1) and Phase 2 (Ph2) clinical trials within 18 to 24 months.

 

Cancure has combined its founders’ scientific vision and passion with a commitment to meeting the commercial interest of committed investors. This has enabled the company to achieve the optimal blend of management, technology, and intellectual property, fully supported by an expert team which formulates and executes strategic development plans.

 

  • Vision
  • Board & Management
  • Scientific Advisors

NEWS

  • NousCom receives $49M to trial off-the-shelf cancer vaccine
  • AstraZeneca bolts Incyte’s IDO1 immunomodulator to its lung cancer plans
  • Incyte pays MacroGenics $150M for PD-1 inhibitor
  • Gilead buys CAR-T developer Kite Pharma for $12B

Contact

Mr Craig Miles
craig@cancure.com
+61 (0) 408 778 797
PO Box 1177, Broadbeach,
Queensland, Australia 4218

Copyright © 2021 All rights reserved.
  • Twitter
  • Dribbble
Scroll to top